![Robin Swartz](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 988 384 $ al 31/08/2026
Robin Swartz is Chief Operating Officer & Business Officer at Voyager Therapeutics, Inc. since 2024.
Former roles include Director at Sanofi-Aventis, Inc., Vice President-Patient & Product Services at Genzyme Corp., and Vice President-Product Services at Genzyme Therapeutics Ltd. from 2018 to 2020.
Education includes undergraduate studies at Kenyon College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/03/2026 | 286.488 ( 0,46 % ) | 988 384 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Director de Operaciones | 01/02/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | 01/06/2020 |
Sanofi-Aventis, Inc.
 Sanofi-Aventis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Director/Miembro de la Junta | - |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Kenyon College
 Kenyon College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Voyager Therapeutics, Inc.
 Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
Sanofi-Aventis, Inc.
Sanofi-Aventis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
